Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation, especially since it appears there may be a benefit in doing so. Our choice today is maple bourbon. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …

Amid criticism over its approach to Covid-19, the pharmaceutical industry issued a new “declaration” to work closer with intra-governmental groups in order to provide greater access to medicines and vaccines in future pandemics, STAT says. Toward that end, the industry listed three priorities: enhance and streamline product development; speed manufacturing to generate high volumes of products; and allocate supplies to priority populations. But governments should widen clinical trial networks, boost regulatory approval strategies, fund pandemic preparedness and procurement mechanisms for low-income countries, not issue trade restrictions, and maintain intellectual property rights.


An expert panel that advises the U.S. Centers for Disease Control and Prevention on vaccine policy voted to recommend use of the Novavax Covid-19 vaccine — an achievement a long time in the making for the company, STAT writes. The Advisory Committee on Immunization Practices voted 12-to-0 to recommend the vaccine, with several members expressing hope that the vaccine’s makeup may persuade some people who have been reluctant to get vaccinated against Covid to finally roll up a sleeve. Some people who have refused Covid vaccines have expressed hesitancy over the messenger RNA vaccines produced by Moderna and the Pfizer and BioNTech partnership. CDC Director Rochelle Walensky accepted ACIP’s recommendation within hours of the vote.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.